Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SEP-363856 for Parkinson disease psychosis completed with results posted, detailing efficacy and safety/tolerability findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Parkinson Disease Psychosis | Phase 2 | Status: COMPLETED | Results posted: 2023-06-05